Moody’s Is Gloomy on U.S. Drugmakers’ Credit

For the next year or so, credit ratings for U.S. drugmakers are more likely to fall than to rise, Moody’s said today. In its semi-annual weather report for the sector, the ratings shop noted a few patches of sun — strong profitability and cash flow, diminishing litigation exposure — but plenty of clouds. Along with [...]